Skip to main content

LVTX

Stock
Health Care
Biotechnology

Performance overview

LVTX Price
Price Chart

Forward-looking statistics

Beta
0.40
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

SectorHealth Care
IndustryBiotechnology
Employees37
Market cap$60.2M

Fundamentals

Enterprise value-$31.5M
Revenue$5.0M
Revenue per employee—
Profit margin100.00%
Debt to equity1.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.05
Dividend per share—
Revenue per share$0.19
Avg trading volume (30 day)$45K
Avg trading volume (10 day)$16K
Put-call ratio—

Macro factor sensitivity

Growth+3.1
Credit+11.2
Liquidity-7.0
Inflation+1.9
Commodities+1.7
Interest Rates-0.4

Valuation

Dividend yield0.00%
PEG Ratio-0.68
Price to sales6.96
P/E Ratio-0.68
Enterprise Value to Revenue-6.32
Price to book1.35

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

On Tuesday, LAVA Therapeutics N.V. LVTX initiated a process to review strategic options.

Benzinga (February 28, 2025)
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy

LAVA Therapeutics (LVTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research (July 22, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free